Davidson Investment Advisors Has $17.22 Million Position in AstraZeneca PLC (NASDAQ:AZN)

Davidson Investment Advisors boosted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 2.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 234,231 shares of the company's stock after acquiring an additional 6,456 shares during the quarter. Davidson Investment Advisors' holdings in AstraZeneca were worth $17,216,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Banque Transatlantique SA bought a new position in shares of AstraZeneca during the 4th quarter valued at $26,000. Confluence Investment Management LLC acquired a new position in AstraZeneca during the first quarter worth $27,000. Mascagni Wealth Management Inc. bought a new position in AstraZeneca during the fourth quarter valued at about $29,000. FNY Investment Advisers LLC bought a new position in AstraZeneca during the first quarter valued at about $29,000. Finally, Highline Wealth Partners LLC lifted its position in shares of AstraZeneca by 447.4% in the first quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock worth $31,000 after buying an additional 340 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, BNP Paribas initiated coverage on AstraZeneca in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price objective on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $85.00.

AstraZeneca Stock Performance

Shares of AZN opened at $69.60 on Monday. The company has a market capitalization of $215.85 billion, a PE ratio of 27.95, a price-to-earnings-growth ratio of 1.28 and a beta of 0.37. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The company's fifty day moving average price is $70.78 and its 200 day moving average price is $70.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The company had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same period last year, the business posted $2.06 earnings per share. The firm's revenue was up 7.2% compared to the same quarter last year. As a group, analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.